AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some breast cancer patients. Truqap was approved by the FDA in late 2023 to be used alongside AstraZeneca’s Faslodex to treat a narrower- …

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial. With its practice-changing regimen, Imfinzi is the first immunotherapy …

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

AstraZeneca is discontinuing the late-stage CAPItello-280 trial, which was evaluating its AKT blocker Truqap in patients with metastatic castration-resistant prostate cancer, the pharma announced on Tuesday. The study, which combined Truqap with docetaxel …

AstraZeneca's highly touted Truqap flunks another phase 3 trial

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its first-quarter earnings report, AZ revealed that an interim …

AstraZeneca has plenty coming down the pipeline to appease the bears

AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company’s longer-term potential …

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

AstraZeneca (AZ) has announced that its Calquence (acalabrutinib) regimens have been recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia (CLL). The Committee for Medicinal Products for Human Use ( …

AstraZeneca to scrap trails of Truqap in prostate cancer after interim analysis

Cambridge: UK-pharma major AstraZeneca has announced plans of discontinuing the Phase III trial of its oncology asset Truqap (capivasertib) in prostate cancer, following an interim analysis suggesting that the “drug is unlikely to meet the dual primary …

AstraZeneca’s Truqap fails in another Phase III trial

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to meet its endpoints. The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen- …

EMA committee recommends approval of AstraZeneca's fixed─duration Calquence─based regimens for 1st─line chronic ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated …